Basque Country University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bilbao Spain (1980)

Organization Overview

First Clinical Trial
2009
NCT01073007
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Ana María García de la Fuente | Asociación Instituto de Investigación Sanitaria BioCruces | Basque Country University | Basque Country University, Spain | Basque Health System - Osakidetza | BioCruces Health Research Institute/Cruces University Hospital | Elena Ruiz de Gopegui Palacios | Hospital de Basurto | HOSPITAL OF BASURTO | HOSPITAL OF BASURTO (BILBAO) | Iraia Bidaurrazaga-Letona | Lizar Aguirre Pascasio | Osakidetza-Basque Country Health Service | Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea | Servicio Vasco de Salud Osakidetza, Spain | University of Pais Vasco | University of the Basque Country (UPV-EHU) | University of the Basque Country (UPV/EHU)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Arterial Occlusive Diseases (Phase 4)

Carcinoma, Hepatocellular (Phase 2)

Conjunctivitis (Phase 1)

Conjunctivitis, Allergic (Phase 1)

Dehydration (Phase 4)

Fluoride Poisoning (Phase 3)

Hemorrhage (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Osteogenesis Imperfecta (Phase 1)

Poisoning (Phase 3)

Shock (Phase 2)

Stroke (Phase 4)

Vomiting (Phase 4)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 29